Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | CDC25B | P30305 | 4/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.46 |
| ▸ | CDC25A | P30304 | 2/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401820 | 1.00 | PPARA (0.56) | PPARAPPARGACECTSSPTPN1 | |
| SCHEMBL3429311 | 0.88 | ACE (0.56) | PPARAPPARGACECTSSPTPN1 | |
| SCHEMBL17642069 | 0.88 | ACE (0.56) | PPARAPPARGACECTSSPTPN1 | |
| SCHEMBL18468298 | 0.88 | ITGB3 (0.48) | PPARAPPARGCTSSCTSLCTSB | |
| SCHEMBL6324267 | 0.86 | ACE (0.52) | PPARAPPARGACECTSSPTPN1 | |
| SCHEMBL12942569 | 0.83 | CPB2 (0.49) | ACEPTPN1CTSKITGB3ITGA2B | |
| SCHEMBL5358340 | 0.82 | MAPT (0.46) | PPARAPPARGACECTSSCTSL | |
| SCHEMBL13711132 | 0.82 | PPARA (0.51) | PPARAPPARGACECTSSPTPN1 | |
| SCHEMBL6329225 | 0.80 | CPB2 (0.64) | PPARAPPARGACEPTPN1ITGB3 | |
| SCHEMBL19508750 | 0.80 | KLK5 (0.51) | PPARAPPARGACECTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VITALIXIR (BEIJING) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| CN-118679179-B | Long-acting GLP-1 polypeptide compound, composition and application thereof | 内蒙古博睿精创科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-113614102-B | Novel polypeptides and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118126124-A | Bioactive polypeptide with QRRAD structure, composition and application thereof | 深圳市肽金生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240067694-A1 | SYNTHESIS OF TEDUGLUTIDE | BIOCON LIMITED (IN) | 2024-02-29 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| EP-3524261-B1 | EXENDIN FOR USE IN TREATING DIABETES AND REDUCING BODY WEIGHT | AMYLIN PHARMACEUTICALS LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230263896-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | VITALIXIR (BEIJING) CO., LTD (CN) | 2023-08-24 | — | — | US | disclosed |
| EP-4177263-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | Vitalixir (Beijing) Co., Ltd (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220127323-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF | VITALIXIR (BEIJING) CO., LTD (CN) | 2022-04-28 | — | — | US | disclosed |
| US-11285103-B2 | Degradable hydrogel under physiological conditions | HAN JIE (CN) | 2022-03-29 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VIP, GCG, GLS | PPARA 3619/4885PPARG 1881/4885ACE 940/4885 |
| US-20220127323-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF | VIP, IAPP, LNPEP | PPARA 3025/4885PPARG 4089/4885ACE 297/4885 |
| US-11285103-B2 | Degradable hydrogel under physiological conditions | PTMS, TRHDE, PHYKPL | PPARA 4036/4885PPARG 3417/4885ACE 2491/4885 |
| US-20230263896-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | VIP, IAPP, LNPEP | PPARA 2927/4885PPARG 3932/4885ACE 286/4885 |
| US-20240067694-A1 | SYNTHESIS OF TEDUGLUTIDE | DNPEP, GCLC, PTMS | PPARA 3983/4885PPARG 4024/4885ACE 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.